

Basal Cell Carcinoma of the Skin to Tirana-Albania

¹Panajot Papa, M.D. PhD

¹Ilma Robo, M.D.

¹Doris Mingomataj, PhD.

²Kristo Papa, M.D. PhD.

¹Faculty of Medical Science, Albanian University Tirana, Albania
²Department of Cardiovascular Sciences, University of Verona Italy
Email: panajotpapa@gmail.com

Doi:10.5901/ajis.2015.v4n2s2p100

Abstract

Basal cell carcinoma (BCC) is the most frequent epithelial tumor of the skin, characterized by a local infiltrative growth in contrast to a very rarely metastatization. In rare cases this neoplastic process behaves aggressively with deep invasion and high recurrence risk after surgery. The pathogenesis and the factors that determine the extensive growth are not completely understood. The American Joint Committee on Cancer published on 1988 the morphologic characteristics necessary to define a BCC as giant. Only the 1% of all BCC achieves these parameters. Basal Cell Carcinoma is linked to a spontaneous mutation of PTCH gene situated in chromosome region 9q22.3. Environmental factors, as sun exposition, trauma or smoking, play an important role in the tumor development. The tumor on sets most frequently in the middle part of the face and scalp even that it can develop on all sun exposed skin. Aim of this study is to review the available literature on BBCs. Between April 2014 and March 2015, 50 patients with BCC were treated in the Department of Plastic and Reconstructive Surgery of Tirana. According to the AJCC classification, 40 tumors were T1 (80%), 5 tumors were T2 (10%) and 5 were T3 (5%). All patients received surgical excision of neoforation and immediate reconstruction. For small BCC (1-2cm), the surgical excisions require clinical margin of 3-5mm and the recurrence risk in this tumor is 4%-14%. Actually the gold standard is to perform a one-step or two-step surgery. In one step surgery the surgical defect is close directly and the reconstructive procedure is definitive. One step surgery, using Mohs Micrographic surgery, affords superior clinical outcomes, with a five-years tumor-free rate of over 99% for primary BCC and over 95% for recurrent BCC, compared to the rate of 93% and 80% respectively for other interventions. Collected data from our personal experience, according with the literature review, demonstrate that early diagnosis on association with the correct treatment is the only strategy to have a good prognosis of the disease.

Keyword: Basal cell carcinoma, Skin tumor

1. Introduction

Basal Cell Carcinoma (BCC) is the most frequent non-melanoma skin tumor. The incidence increase is distributed in not uniform way; USA and Australia present the great rate (30%) (Schroeder, et al., 2001; Walling, et al., 2004). The risk of developing a BCC in patients with prior BCC is estimated at 44% in three years (Burns, et al., 2002). The neoplasm is most commonly diagnoses in older (age range 40-80), fair skinned individual but in literature are reported numerous cases onset in young or in other races.

The etiopathogenesis of BCC is linked to a spontaneous mutation of PTCH gene situated in chromosome region 9q22.3 (Efron, et al., 2008). In literature are described numerous genetic disorders associated to basal cell carcinoma (Gorlin Syndrome, Xeroderma pigmentosum). (Marcil, & Stern, 2000; Gorlin, 1995). Enviromental factors, as sun exposition, trauma or smoking, play an important role in the tumor development. (D'Hermies, & Renard, 2005; Fandon, et al., 1994; McElroy, 1996).

The tumor on sets most frequently in the middle part of the face and scalp, even that it can develop on all sun exposed skin.

BCC is characteristically composed by small basaloid cell with an oval, monomorphous nucleus, organized in cluster that invades normal tissue, generally grows slowly and behaves in a relatively benign, less aggressive fashion. Giant BCC is, on contrary, a rare skin malignancy characterized by an aggressive biological behavior, deep tissue

invasion with infiltration of the dermis or extradermal structures (muscle, bone, etc.), frequent metastasis and a poor prognosis.

As define by the American Joint Committee on Cancer the Giant Basal Cell carcinoma is a tumor of 5cm or more greatest dimension (T3), while others define as "giant" the carcinomas larger than 10cm.

Aim of this study is to review the available literature on BBCs and describe the Author personal series.

2. Materials and Methods

2.1 Literature review

Articles pertaining to Basal Cell Carcinoma of the skin were identified by performing a literature search using the National Library of Medicine's Pub Med, The Cochrane Collaboration, Embase and Scopus. The following search terms were used: "Basal Cell Carcinoma", "BCC", "Aggressive basal cell carcinoma", and "Metastatic BCC".

2.2 Personal experience

Between April 2014 and March 2015, 50 patients with BCC were treated in the Department of Plastic and Reconstructive Surgery of Tirana-Albania. According to the AJCC classification, 40 tumors were T1 (80%), 5 tumors were T2 (10%) and 5 were T3 (5%). The time between tumor occurrence and diagnosis correlated with size. BCC were associated with lesion presence between five and ten years. All patients received surgical excision of neof ormation and immediate reconstruction. (Myers, & Gurwood, 2001).

In four cases we performed the regional lymphadenectomy. No lymph node metastases were found. In five non surgical cases (all BCC were located in face), two patients were in no good health conditions and were referred to dermatologic department to receive a PDT (lost to follow-up). One patient, affected by superficial BCC, refused surgical excision and was treated with Laser CO₂, but after many attempts to have patient return for treatment, he was lost to follow-up; and four refused any treatment for aesthetic reasons. Skin grafts and local flaps were used for reconstruction

3. Risk factor

Traditionally some clinical features are strongly linked to an aggressive phenotype of BCC.

Large size, facial location, neglect or long standing tumor are reported as important factor for GBCC development. (Walther, et al., 2004).

Large size at first examination plays an important role on prognosis: Vico et al suggested that 1cm size is the limit over which the malignant behavior changes. (Walling, et al., 2004). Usually large size is the result of long standing tumors or a rapid grow due a particular histotype. (Fandon, et al., 1994).

Not completely clear is the link with the onset in the middle face area, as reported in many works the tumor development on medial cantus or on the naso-labial fold are characterized by a more aggressive course. (Sahl, 1994). This may stem from the close proximity of the skin to the bone and cartilaginous structures. (Sahl, 1994).

Incomplete excision is consider as a risk factor due to the presence of scar tissue, which obscure monitoring and delays clinical detection of recurrence (Walling, et al., 2004), but J.D. Richmond et al. reports that there aren't evidences that inadequate treatment modifies the tumor behavior.

Recently some author focus the attention tension on histologic variant and on particular features as perivascular and perineural invasion. (Sahl, 1994; McElroy, 1996).

Nodular and superficial BCC are the varieties of neoplasm tending to be less aggressive [25,26 art1], morpheaform, infiltrating are associated with high risk of Giant Basal Cell Carcinoma development.

As reported previously, the last features underlining an aggressive behavior is the invasion of vascular and nervous structure. These hystologic findings are extremely rare to be identified: as reported in literature the perivascular diffusion may contribute to tumor extension by increasing the neoplastic tissue trophism. Instead the neuronal involvement, present in the 10% of aggressive Bcc, is considering a risk factor for rapid diffusion due the low resistance cleavage plane along the nerve fiber.

Other hystologic aspect, that may be consider as minor criteria are: inflammatory infiltrate, fibrosis, palisadism and increased of mitotic rate (Schroeder, et al., 2001; Walling, et al., 2004). Appear intuitive that a high number of mitotic figures are linked to a rapid cellular turnover, but the role of inflammatory infiltration has to be clarify.

4. Discussion

Basal cell carcinoma is the most common skin cancer that predominantly occurs on sun-exposed and sun-damaged areas. BCC generally demonstrates a relatively innocuous course, with slow growth and only minimal local invasion.

Occasionally it demonstrates an aggressive phenotype with local invasion, destroying nearby structures with resultant loss of function. The incidence of BCC is increasing rapidly, such that the lifetime risk of developing it is above 30 percent.

Basal cell carcinoma arise from the pluripotential epithelial cell of the epidermis and grows at a rate of 1mm in diameter per year but, aggressive BCC can increase their dimension more quickly.

Giant BCC is a rare variant that infiltrates extra dermal structures such as bone, muscle and cartilage. The American Joint Committee on Cancer defines Giant BCC as a tumor larger than 5cm; fortunately only one percent achieves this size although in our series the 2.27% of patient had a tumor larger than 5cm. We think that a high rate like our report is linked to the advanced average age of our patient, to the geographic position, their job (farmer, bricklayer, etc) and to their lower scholastic profile.

As emerges from our series and from literature review, the biggest tumor had been developed four- seven years before the diagnosis. This delay became longer in the small community there the skin problems are not correctly estimate and receive an inadequate treatment with a recurrence rate approximately of 12%. (Burns, et al., 2002).

In literature spontaneous regression of incompletely excised small BCCs are reported to be a common phenomenon. Different is for the Giant Basal Cell Carcinoma that present a high recurrence rate.

In five of non complete resection, in our series, we observe the recurrence of BCC just 2 months from surgery. In 1 case the skin graft was rejected in the residual neoplastic area allowing to us reach the radicality with a second surgical time.

The metastasis cases are very rare, Beadles in 1894 described the first one (Reis, et al., 1992).

Snow and Sahj confirmed that while metastases occur with an overall incidence of 0.03%, with carcinomas greater than 3cm in diameter the incidence of metastases raises to 1.9%. Metastases occur in 45% of lesions larger than 10cm and in 100% of tumors greater than 25cm.

In the second half of '900 some authors proposed a list of criteria to define a BCC as metastatic:

1. The primary lesion exists in skin and not in mucosa,
2. Metastases occur at a distant site and are not the result of extension from primary lesion,
3. Histology for the primary and metastatic lesion should be similar,
4. Squamous cell features must not be present in the lesion. (Burns, et al., 2002; Gorlin, 1995).

In our patients there aren't cases of diffuse pathology, in fore limphectomys we didn't found neoplastic infiltrate. We observed two deaths not for metastasis but for the involvement of intracranial structures secondary to the surgical treatment refuse by patient. This open problem in oncologic surgery, more patients refuse surgery because doesn't understand the problem or refuse the scar.

As reported by patients, during the early form, theses lesion are painless and doesn't create disturbance specially when located in the trunk. In cases of face involvement the patient is referred to the surgeon when the tumor reached great dimension, compromises the involved structures functions and the smell tissue affects the social life.

Walling, et al., (2004) describes a typical case in which the patient refused surgery for esthetic reasons despite the presence of an oncologic disease. This situation often results in an unacceptable delay in treatment and a consequent necessity to perform a more radical and destructive curative procedure.

Informed consent is recognized as a key component of the doctor-patient relationship. During any patient interview, the physician must discuss the benefits and the risks of the proposed procedure, as well as the consequences of treatment refusal and the likely prognosis. Nevertheless, some patients will refuse treatment, resulting in surgeon frustration.

Physicians must remember that a patient may refuse surgery as long as they are able to understand the outcome of their decision and are able to act in their own best interest. A competent patient has the right to refuse any treatment, even if it will shorten their life, and to instead choose suboptimal treatment as an option if they feel it provides the best quality of life. It is not uncommon for people with chronic or severe illnesses to refuse treatment, even when that decision is going to result in their death.

Is commonly accepted that surgery is the first choice to treat Basal Cell Carcinoma. (Walling, et al., 2004). For small BCC (1-2cm), the surgical excision require clinical margin of 3-5mm and the recurrence risk in this tumor is 4%-14%. In BCC the surgery request more wide safety margin (10mm) and the risk of tumor residue is 68%. (Archontaki, et

al., 2009).

Actually the gold standard is to perform a one-step or two-step surgery. (D'Hermies, & Renard, 2005). In one step surgery the surgical defect is close directly and the reconstructive procedure is definitive. [vb14,15 art 3] The problems associate with this surgery is the health margin control. One step surgery, using Mohs Micrographic surgery, affords superior clinical outcomes, with a five-years tumor-free rate of over 99% for primary BCC and over 95% for recurrent BCC, compared to the rate of 93% and 80% respectively for other interventions. (Burns, et al., 2002).

However, some authors prefer a delayed reconstruction and the final defect closure is done only after the definitive histopathological answer is given. (Archontaki, et al., 2009).

Extended surgery with the resection of important structure, like bone, dura mater or nervous structure, result in a complex defect that can lead to the lethal outcome. Reconstruction became an interdisciplinary procedure involving plastic surgeon, neurosurgeon, vascular surgeon anaesthesiologist and other. (Marcil, & Stern, 2000; Reis, et al., 1992).

The reconstructive procedure can vary from split skin graft to free flap transfer. The choice is linked to the BCC position, the donor site availability and the patient general health condition. In BCC less than 2cm we prefer to have reconstruction with Skin graft o local cutaneous flap. In front of Giant one the reconstructive became a challenge, particularly when lesion occurs in aesthetically or functionally sensitive areas, so we obtain reconstruction using composite flaps.

According to the literature, the surgical procedures, not followed by histological control, such us cryosurgery, electrodesiccation, Laser CO₂, have a high risk of recurrence. (Schroeder, et al., 2001; Chew, 2007).

Chemotherapy or radiotherapy is quite effective for disease control.

In particular radiotherapy may result in increasing risk of delayed healing or pathologic scar. (Sahl, 1994). Radiation therapy can be considered as adjuvant or palliative option (Schroeder, et al., 2001; Burns, et al., 2002).

The relatively recent introduction of non-surgical tissue sparing treatment modalities for BCC shows potential application in the management of giant basal cell carcinoma. As reported by Sahl, et al., this procedure may aid in obtaining adequate margin clearance during the surgical excision.

In our practice we reserve non surgical treatment only in case in which patient refuses the surgical excision or when the general and local conditions not allow an aggressive procedure.

5. Conclusions

Basal Cell Carcinoma is a variant of non melanoma skin cancers that grew to a very large size because patients admittedly neglected seeking treatment. Neglect may be the result of denial, cognitive impairment (psychiatric disorders) or patient's awareness based on educational background. Collected data from our personal experience, according with the literature review, demonstrate that early diagnosis on association with the correct treatment is the only strategy to have a good prognosis of the disease.

References

- Schroeder, M., Kestlmeier, R., Schegel, J., & Trappe, A. (2001). Extensive cerebral invasion of a basal cell carcinoma of the scalp. *Eur J SurgOncol.*, 27, 510–511.
- Chew, R. (2007). Destruction of the orbit and globe by recurrence of basal cell carcinoma. *Optometry*, 78, 344–351.
- D'Hermies, A.J., & Renard, F. (2005). Basal cell carcinomas of the eyelids. *Ophthalmologica*, 219, 57–71.
- Walling, HW., Fosko, SW., Geraminejad, P.A., Whitaker, D.C., & Arpey, C.J. (2004). Aggressive basal cell carcinoma: presentation, pathogenesis, and management. *Cancer Metastasis Rev*, 23, 389–402.
- Efron, P.A., Chen, M.K., Glavin, F.L., Kays, D.W., & Beierle, E.A. (2008). Pediatric basal cell carcinoma: case reports and literature review. *J PediatrSurg*, 43, 2277–2280.
- Marcil, I., & Stern, R.S. (2000). Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. *Arch Dermatol*, 136, 1524–1530.
- Burns, F.J., Shore, R.E., Roy, N., Loomis, C., & Zhao, P. (2002). PTCH (patched) and XPA genes in radiation-induced basal cell carcinomas. *IntCongrSer*, 1236, 175–178.
- Gorlin, R. (1995). Nevoid basal cell carcinoma syndrome. *DermatolClin*, 13, 113–125.
- Reis, A., Kuster, W., & Linss, G. (1992). Localisation of gene for the naevoid basal-cell carcinoma syndrome. *Lancet*, 339, 328–617.
- Farndon, P.A., Morris, D.J., & Hardy, C. (1994). Analysis of 133 meioses places the genes for nevoid basal cell carcinoma (Gorlin) syndrome and Fanconi anemia group C in a 2.6-cM interval and contributes to the fine map of 9q22.3. *Genomics*, 23, 486–489.
- Myers, M., & Gurwood, A.S. (2001). Periocular malignancies and primary eye care. *Optometry*. 72, 705–712.
- Walther, U., Kron, M., & Sander, S. (2004). Risk and protective factors for sporadic basal cell carcinoma: results of a two-centre case-

- control study in southern Germany. Clinical actinic elastosis may be a protective factor. *Br J Dermatol*, 151, 170–178.
- Archontaki, M., Stavrianos, S.D., & Korkolis, D.P. (2009). Giant Basal cell carcinoma: clinicopathological analysis of 51 cases and review of the literature. *Anticancer Res*, 29, 2655–2663.
- Sahl, W.J. Jr., Snow, & S.N., Levine, N.S. (1994). Giant basal cell carcinoma. Report of two cases and review of the literature. *J Am Acad Dermatol*, 30, 856–859.
- McElroy, J., Knight, T.E., & Chang-Stroman, L. (1996). Giant polypoid basal cell carcinoma. *Cutis*, 58, 289–292.